Announcement & Circular
Corporate Governance
Financial Results
IR Activities
Contact Us
Announcement & Circular
Stock Information
02186.HK
2.39 0.02  (0.84%)
TradingVolume：4242.15
02-05
2025
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 January 2025
Publisher：
01-15
2025
FIRST PATIENT ENROLLED FOR THE PHASE 2 CLINICAL STUDY OF THE GROUP'S NEW DRUG LY03015 IN CHINA
Publisher：
01-14
2025
APPROVAL OBTAINED FOR THE GROUP'S NEW DRUG LY03020 FOR CLINICAL TRIALS IN THE U.S.
Publisher：
01-02
2025
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 December 2024
Publisher：
12-18
2024
INCREASE IN SHAREHOLDING IN THE COMPANY BY CONTROLLING SHAREHOLDER
Publisher：
12-16
2024
OVERSEAS REGULATORY ANNOUNCEMENT
Publisher：
12-13
2024
COMPLETION OF THE ISSUE OF US$50,000,000 5.85 PER CENT. CONVERTIBLE BONDS DUE 2025
Publisher：
12-03
2024
APPROVAL OF ZEPZELCA (LURBINECTEDIN FOR INJECTION) FOR MARKETING IN MAINLAND CHINA
Publisher：
12-02
2024
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 November 2024
Publisher：
11-28
2024
RUOXINLIN AND OTHER DRUGS INCLUDED ON CHINA'S 2024 NATIONAL REIMBURSEMENT DRUG LIST
Publisher：
First
1
2
3
4
5
Last
Investors
Announcement & Circular
Corporate Governance
Financial Results
IR Activities
Contact Us
Stock Information
02186.HK
TradingVolume：4242.15
2.39
0.02  (0.84%)
Announcement & Circular
02-05
2025
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 January 2025
01-15
2025
FIRST PATIENT ENROLLED FOR THE PHASE 2 CLINICAL STUDY OF THE GROUP'S NEW DRUG LY03015 IN CHINA
01-14
2025
APPROVAL OBTAINED FOR THE GROUP'S NEW DRUG LY03020 FOR CLINICAL TRIALS IN THE U.S.
01-02
2025
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 December 2024
12-18
2024
INCREASE IN SHAREHOLDING IN THE COMPANY BY CONTROLLING SHAREHOLDER
12-16
2024
OVERSEAS REGULATORY ANNOUNCEMENT
12-13
2024
COMPLETION OF THE ISSUE OF US$50,000,000 5.85 PER CENT. CONVERTIBLE BONDS DUE 2025
12-03
2024
APPROVAL OF ZEPZELCA (LURBINECTEDIN FOR INJECTION) FOR MARKETING IN MAINLAND CHINA
12-02
2024
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 November 2024
11-28
2024
RUOXINLIN AND OTHER DRUGS INCLUDED ON CHINA'S 2024 NATIONAL REIMBURSEMENT DRUG LIST
First
1
2
3
4
5
Last